Welcome to our dedicated page for Eupraxia Pharmac news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmac stock.
Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported sustained positive outcomes from its RESOLVE Phase 1b/2a trial of EP-104GI for eosinophilic esophagitis (EoE) treatment. After 9 months, patients receiving 48mg EP-104GI showed sustained or improved treatment outcomes. Key findings include:
- All patients reported reduced symptom severity, with up to 100% reduction and average 65% improvement in SDI scores
- 56% reduction in tissue health (EoEHSS Stage) and 45% reduction in Grade score
- 77% mean decrease in eosinophil counts with 52% remission rate
- One patient maintained complete histologic remission from 3 through 9 months
The 6-month data for the 64mg cohort showed up to 86% reduction in symptom severity. The company plans to release additional long-term data with higher doses in Q3 2025.
Eupraxia Pharmaceuticals (NASDAQ/TSX:EPRX) has announced its participation in several key investor and scientific conferences during April and May 2025. The company will showcase research on two main products: EP-104IAR for knee osteoarthritis and EP-104GI for eosinophilic esophagitis (EoE).
At the OARSI World Congress in South Korea (April 24-27), Dr. Phil Conaghan will present findings on EP-104IAR's sustained pain response in knee osteoarthritis patients. The Digestive Disease Week in San Diego (May 3-6) will feature two presentations: Dr. Evan Dellon will discuss EP-104GI's Phase 1b/2a study results, while Dr. Amanda Malone will present on esophageal strictures epidemiology.
Additional presentations include CEO Dr. James Helliwell at the Bloom Burton & Co. Healthcare Investor Conference (May 5-6) in Toronto, and Dr. Arjan Bredenoord at the ESDE Annual Congress (May 11-13) in Amsterdam.
Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) reported Q4 2024 financial results, highlighting positive developments in its clinical trials. The company posted a net loss of $7.5 million for Q4 2024, an improvement from the $10.6 million loss in Q4 2023. Cash position strengthened to $33.1 million as of December 31, 2024, up from $19.3 million year-over-year.
Key highlights include compelling data from the Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis, with improved tissue health and symptom reduction outcomes at higher doses. The company successfully raised C$44.5 million through a private placement, extending its funding runway into Q3 2026.
The company is monitoring potential impacts of proposed 25% U.S. tariffs on Canadian goods and planned Canadian retaliatory tariffs, as it sources API and manufactures clinical supplies in the U.S.
Eupraxia Pharmaceuticals announced positive data from its RESOLVE Phase 1b/2a trial of EP-104GI for treating Eosinophilic Esophagitis (EoE), an inflammatory disease causing difficulty swallowing. The trial showed consistent improvements in histological scores and symptom relief as dosage and esophageal coverage increased.
Cohort 6 demonstrated the most significant results to date, with the greatest symptom relief scores at 12 weeks, largest improvements in tissue health scores, and highest reduction in Peak Eosinophil Count. Cohort 5 showed the greatest symptom score reduction at 24 weeks, with continuously improving relief over time.
Notably, a clear dose-response was observed from Cohorts 3 to 6, with no serious adverse events or oral/gastrointestinal candidiasis reported across all six cohorts. The company believes EP-104GI could become a new standard of care for EoE treatment, with Cohort 7 fully enrolled and 12-week data expected in Q2 2025.
Eupraxia Pharmaceuticals (NASDAQ: EPRX) (TSX: EPRX) has appointed Alex Rothwell as its new Chief Financial Officer, replacing retiring CFO Bruce Cousins, who will remain as a consultant for the transition period. Rothwell, who previously served as Eupraxia's CFO from 2018-2021, brings over 25 years of experience in capital markets and investment banking.
Rothwell's background includes leadership roles at Canadian investment banks, including serving as President and Executive Director of Macquarie Capital Markets Canada. Throughout his career, he has helped raise billions in funding through various structures from early-stage investments to IPOs. He holds a Bachelor of Chemical Engineering from McGill University and an MBA from the Ivey School of Business.
The new CFO expressed optimism about Eupraxia's potential, particularly highlighting EP-104GI for Eosinophilic Esophagitis treatment and EP-104IAR for osteoarthritis knee pain.
Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) revealed new pharmacokinetic data from its Phase 2a Eosinophilic Esophagitis program, highlighting its DiffuSphere™ technology. The platform demonstrates targeted drug delivery maintaining therapeutic levels for over six months while minimizing systemic exposure. In clinical trials, DiffuSphere™ showed successful delivery of fluticasone propionate in both EoE and osteoarthritis patients. The technology's unique microsphere composition enables precise drug release into target tissues with a stable profile, achieving high local concentrations while minimizing systemic exposure. Clinical data showed steady drug levels of 1.5 pg/ml for six months in EoE patients at 4mg dose, and 10pg/ml at three months with 48mg dose.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced its participation in the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting in Washington, D.C., November 14-19, 2024. The company will present a poster (Number 2106) titled 'EP-104IAR Shows Sustained Improvement in Pain for Subjects with Moderate Baseline Pain and BMI Less Than 30 in SPRINGBOARD.' The presentation focuses on their long-acting intra-articular injection of fluticasone propionate for knee osteoarthritis. Philip G. Conaghan will present the findings on November 18, 2024, from 10:30 a.m. to 12:30 p.m. ET. The poster will be available on Eupraxia's website.
Eupraxia Pharmaceuticals (TSX: EPRX) (NASDAQ: EPRX) announced that CEO Dr. James A. Helliwell will present at a Tribe Public Webinar focused on Eosinophilic Esophagitis (EoE), a digestive disorder affecting over 450,000 people in the United States. The presentation, titled 'Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed,' is scheduled for November 15, 2024, at 8:30 am PT / 11:30 am ET.
The event is open to public registration at EPRXNOV1524.TribePublic.com. Participants can submit questions in advance via email or during the event through ZOOM chat. The webinar will be hosted by Tribe Public's Managing Member, John F. Heerdink, Jr.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced positive data from the fifth cohort of its RESOLVE Phase 1b/2a trial for EP-104GI in treating Eosinophilic Esophagitis (EoE). Key highlights include: one patient achieving complete histological remission at 12 weeks, consistent improvement in patient-reported outcomes, and the largest average reduction in symptom scores observed in the fourth cohort at 24 weeks. The fifth cohort showed the greatest percentage change in histology scores to date, with clear dose response across Cohorts 3 to 5. No serious adverse events were reported, and Cohort 6 is fully enrolled with data expected in Q1 2025.